252 related articles for article (PubMed ID: 35281041)
1. Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical Outcome
Jiang A; Meng J; Gong W; Zhang Z; Gan X; Wang J; Wu Z; Liu B; Qu L; Wang L
Front Immunol; 2022; 13():842069. PubMed ID: 35281041
[TBL] [Abstract][Full Text] [Related]
2. POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma.
Tian J; Cheng C; Gao J; Fu G; Xu Z; Chen X; Wu Y; Jin B
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047824
[TBL] [Abstract][Full Text] [Related]
3. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.
Bao Y; Jiang A; Dong K; Gan X; Gong W; Wu Z; Liu B; Bao Y; Wang J; Wang L
Int J Biol Sci; 2021; 17(12):3158-3172. PubMed ID: 34421357
[TBL] [Abstract][Full Text] [Related]
4. CCNA2 as an Immunological Biomarker Encompassing Tumor Microenvironment and Therapeutic Response in Multiple Cancer Types.
Jiang A; Zhou Y; Gong W; Pan X; Gan X; Wu Z; Liu B; Qu L; Wang L
Oxid Med Cell Longev; 2022; 2022():5910575. PubMed ID: 35401923
[TBL] [Abstract][Full Text] [Related]
5. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
[TBL] [Abstract][Full Text] [Related]
6. Key sunitinib-related biomarkers for renal cell carcinoma.
Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
[TBL] [Abstract][Full Text] [Related]
7. Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma.
Yuan H; Qin X; Yang Q; Liu L; Fang Z; Fan Y; Xu D
Biol Sex Differ; 2023 Jul; 14(1):46. PubMed ID: 37434223
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma.
Long Q; Huang C; Huang J; Meng Q; Cheng Y; Li Y; He L; Chen M; Zhang C; Wang X; Zhu W; Peng J; Shi D; Zheng F; Dong P; Deng W
J Adv Res; 2022 Sep; 40():153-166. PubMed ID: 36100323
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
10. Risk signature identification and NPRL2 affects sunitinib sensitivity in clear cell renal cell carcinoma.
Du X; Zhao Z; Zhao X; Wang H; Jiang L; Tang W
Biochem Biophys Res Commun; 2023 Jun; 663():122-131. PubMed ID: 37121122
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of serine metabolism enzyme PSAT1 predicts poor prognosis and promotes proliferation, metastasis and drug resistance of clear cell renal cell carcinoma.
Ye J; Huang X; Tian S; Wang J; Wang H; Feng H; Zhao X; Cao S; Xuan Y; Li X; Ma X; Huang Y; Zhang X
Exp Cell Res; 2024 Apr; 437(1):113977. PubMed ID: 38373588
[TBL] [Abstract][Full Text] [Related]
12. An immune-related lncRNA risk coefficient model to predict the outcomes in clear cell renal cell carcinoma.
Tang C; Qu G; Xu Y; Yang G; Wang J; Xiang M
Aging (Albany NY); 2021 Dec; 13(24):26046-26062. PubMed ID: 34954690
[TBL] [Abstract][Full Text] [Related]
13. Identification of candidate biomarker
Lv Q; Xiao W; Xiong Z; Shi J; Miao D; Meng X; Yuan H; Yang H; Zhang X
Front Biosci (Landmark Ed); 2021 Nov; 26(11):1176-1190. PubMed ID: 34856762
[No Abstract] [Full Text] [Related]
14. High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma.
Zhu ZP; Lin LR; Lv TD; Xu CR; Cai TY; Lin J
Oncol Rep; 2020 Nov; 44(5):2056-2066. PubMed ID: 33000227
[TBL] [Abstract][Full Text] [Related]
15. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
[TBL] [Abstract][Full Text] [Related]
16. CPA4 as a biomarker promotes the proliferation, migration and metastasis of clear cell renal cell carcinoma cells.
Wang K; Ding Y; Liu Y; Ma M; Wang J; Kou Z; Liu S; Jiang B; Hou S
J Cell Mol Med; 2024 Apr; 28(7):e18165. PubMed ID: 38494845
[TBL] [Abstract][Full Text] [Related]
17. FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity.
Dong K; Chen W; Pan X; Wang H; Sun Y; Qian C; Chen W; Wang C; Yang F; Cui X
BMC Cancer; 2022 Feb; 22(1):140. PubMed ID: 35120484
[TBL] [Abstract][Full Text] [Related]
18. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
19. Downregulation of
Wang T; Xie F; Li YH; Liang B
Future Oncol; 2021 Dec; 17(36):5033-5044. PubMed ID: 34704468
[TBL] [Abstract][Full Text] [Related]
20. High SNRPA1 expression leads to poor prognosis in patients with lung adenocarcinoma.
Yang JJ; Yang YJ; Gu YL; Tong L; Liu YF; Zhang JG
Clin Respir J; 2023 Aug; 17(8):719-732. PubMed ID: 37277111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]